lung cancer | |||||
新闻 | |||||
Zongertinib Offers "The Best Toxicity Profile I Have Ever Seen," Santos Says Even though HER2 has shown to be a driver mutation in lung cancer, we still don't have a medication that is approved by the FDA as a frontline [ ...
| |||||
查看更多结果 | 修改此快讯 |
您收到此电子邮件是因为您订阅了Google快讯。 |
以RSS Feed的形式接收此快讯 |
发送反馈 |
No comments:
Post a Comment